Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2010

01-12-2010 | Translational Research and Biomarkers

Evaluation of the Association of Urokinase Plasminogen Activator System Gene Polymorphisms with Susceptibility and Pathological Development of Hepatocellular Carcinoma

Authors: Chia-Jui Weng, PhD, Chiung-Man Tsai, MS, Yi-Chen Chen, PhD, Yi-Hsien Hsieh, PhD, Chiao-Wen Lin, MS, Yu-Fan Liu, PhD, Shih-Chi Su, MS, Mu-Kuan Chen, PhD, Shun-Fa Yang, PhD

Published in: Annals of Surgical Oncology | Issue 12/2010

Login to get access

Abstract

Background

The urokinase plasminogen activator (uPA) system is a serine proteinase system involved in extracellular matrix (ECM) degradation. The levels of uPA system components in tumor tissues are implicated as prognostic biomarkers in a wide range of malignancies. Although the contributions of uPA system components to the formation of many types of cancer are well known, their possible association with the prediction of risk and prognosis of hepatocellular carcinoma (HCC) remains poorly investigated.

Methods

A total of 102 HCC patients and 344 controls were recruited. Genetic polymorphisms of uPA system genes, including uPA, uPA receptor (uPAR), and plasminogen activator inhibitor (PAI)-1, were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotyping analysis.

Results

When individuals were classified into male and female subgroups to estimate adjusted odds ratios (AORs) with their 95% confidence intervals (CIs) of each uPA system gene, the HCC risks of males and females with PAI-1 5G/5G genotype were 6.06-fold (95% CI = 1.39–26.36) and 0.04-fold (95% CI = 0.003–0.69), respectively, as compared with those with PAI-1 4G/4G genotype. High risk for hepatitis B surface antigen (HBsAg)-positive clinical status and significantly higher serum aspartate aminotransferase (AST) concentration were exhibited in HCC patients with PAI-1 4G/5G and 5G/5G genotypes as compared with 4G/4G homozygotes.

Conclusions

The results suggest that PAI-1 genotypes could be an important factor contributing to increased susceptibility and pathological development of HCC in Taiwanese population.
Literature
1.
2.
Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–43.CrossRefPubMed
3.
Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–22.CrossRefPubMed
4.
Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1–22.CrossRefPubMed
5.
Danø K, Rømer J, Nielsen BS, Bjørn S, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling—cooperation of protease systems and cell types. APMIS. 1999;107:120–7.CrossRefPubMed
6.
Duffy MJ, Maguire TM, McDermott EW, O’Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999;71:130–5.CrossRefPubMed
7.
Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34:122–36.CrossRefPubMed
8.
Sakakibara T, Hibi K, Koike M, et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer. 2005;93:799–803.CrossRefPubMed
9.
Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005;14:105–12.PubMed
10.
Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer. 1997;76:622–7.PubMed
11.
Fredstorp-Lidebring M, Bendahl PO, Brunner N, Casslen B, Hogberg T, Langstrom-Einarsson E, et al. Urokinase plasminogen activator and its inhibitor PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur J Cancer. 2001;37:2339–48.CrossRefPubMed
12.
Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumour size. Cancer. 1999;86:2602–11.CrossRefPubMed
13.
Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in highrisk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913–20.CrossRefPubMed
14.
Klinger KW, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielsen LS, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3–q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA. 1987;84:8548–52.CrossRefPubMed
15.
Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene. J Biol Chem. 1988;263:9129–41.PubMed
16.
Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in Hep G2 cells. J Biol Chem. 1993;268:10739–45.PubMed
17.
Eriksson P, Kallin B, van ‘t Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851–55.CrossRefPubMed
18.
Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211.CrossRefPubMed
19.
Department of Health, Republic of China. Health statistics: II. Vital statistics. Taipei: Department of Health; 2007.
20.
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.CrossRefPubMed
21.
Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematol Am Soc Hematol Educ Program. 2006;375–80.
22.
Yano Y, Yamashita F, Kuwaki K, Fukumori K, Kato O, Yamamoto H, et al. Clinical features of hepatitis C virusrelated hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int. 2006;26:789–95.CrossRefPubMed
23.
Chang CC, Chen SC, Hsieh YH, Chen YC, Chen TY, Chu YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med. 2009;47:412–8.CrossRefPubMed
24.
Akkız H, Bayram S, Bekar A, Ozdil B, Akgöllü E, Sümbül AT, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. Cancer Epidemiol. 2009;33:261–4.CrossRefPubMed
25.
Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1808–15.CrossRefPubMed
26.
Tsai MC, Kee KM, Chen YD, Lin LC, Tsai LS, Chen HH, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol. 2007;22:92–8.CrossRefPubMed
27.
Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98:257–61.CrossRefPubMed
28.
Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–308.CrossRefPubMed
29.
Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev. 2001;21:146–70.CrossRefPubMed
30.
Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 2007;25:33–9.CrossRefPubMed
31.
Castelló R, Espana F, Vazquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117:487–92.CrossRefPubMed
32.
Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991;17:303–12.CrossRefPubMed
33.
Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J. 1998;316:829–30.
34.
Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23:6986–90.CrossRefPubMed
35.
Alvarez-Millán JJ, Bocos C, Ferrín V, Lucas AR, Ruibal A, Schneider J. PAI-1 promoter polymorphism modulates uPA–PAI complex accumulation by breast cancer cells. Oncology. 2002;62:286–90.CrossRefPubMed
36.
Smolarz B, Blasiak J, Kulig A, et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res. 2001;20:247–52.PubMed
37.
Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, Lenner P, Försti A. PAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat. 2008;109:165–75.CrossRefPubMed
Metadata
Title
Evaluation of the Association of Urokinase Plasminogen Activator System Gene Polymorphisms with Susceptibility and Pathological Development of Hepatocellular Carcinoma
Authors
Chia-Jui Weng, PhD
Chiung-Man Tsai, MS
Yi-Chen Chen, PhD
Yi-Hsien Hsieh, PhD
Chiao-Wen Lin, MS
Yu-Fan Liu, PhD
Shih-Chi Su, MS
Mu-Kuan Chen, PhD
Shun-Fa Yang, PhD
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1124-y

Other articles of this Issue 12/2010

Annals of Surgical Oncology 12/2010 Go to the issue

Gastrointestinal Oncology

7th Edition of the AJCC Cancer Staging Manual: Stomach

Pediatric Oncology

Outcomes of Pediatric Patients with Malignancies of the Major Salivary Glands

Pancreatic Tumors

MicroRNA-203 Expression as a New Prognostic Marker of Pancreatic Adenocarcinoma

Breast Oncology

Pseudoangiomatous Stromal Hyperplasia and Breast Cancer Risk

Thoracic Oncology

Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer

Breast Oncology

The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up